<!--
title: The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
description: PMCID: PMC5835698    PMID: 29511601
published: true
date: 2022-02-11T13:04:27.924Z
tags: ivermectin, cancer, drug, antiparasitic, cure, repurposing
editor: ckeditor
dateCreated: 2022-02-11T13:04:27.924Z
-->

<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/#">Am J Cancer Res.</a> 2018; 8(2): 317–331.</p>
<p>Published online 2018 Feb 1.</p>
<p style="text-align:right;">PMCID: PMC5835698</p>
<p style="text-align:right;">PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/29511601">29511601</a></p>
<p>&nbsp;</p>
<h1>The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug</h1>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Juarez%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29511601">Mandy Juarez</a>,<sup>1</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Schcolnik-Cabrera%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29511601">Alejandro Schcolnik-Cabrera</a>,<sup>1</sup> and <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Due%26%23x000f1%3Bas-Gonzalez%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=29511601">Alfonso Dueñas-Gonzalez</a><sup>2</sup></p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/#">Author information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/#">Article notes</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/#">Copyright and License information</a> <a href="https://www.ncbi.nlm.nih.gov/pmc/about/disclaimer/">Disclaimer</a></p>
<p>This article has been <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/citedby/">cited by</a> other articles in PMC.</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/#">Go to:</a></p>
<p style="text-align:right;">&nbsp;</p>
<h2>Abstract</h2>
<p>Drug repositioning is a highly studied alternative strategy to discover and develop anticancer drugs. This drug development approach identifies new indications for existing compounds. Ivermectin belongs to the group of avermectins (AVM), a series of 16-membered macrocyclic lactone compounds discovered in 1967, and FDA-approved for human use in 1987. It has been used by millions of people around the world exhibiting a wide margin of clinical safety. In this review, we summarize the <i>in vitro</i> and <i>in vivo</i> evidences demonstrating that ivermectin exerts antitumor effects in different types of cancer. Ivermectin interacts with several targets including the multidrug resistance protein (MDR), the Akt/mTOR and WNT-TCF pathways, the purinergic receptors, PAK-1 protein, certain cancer-related epigenetic deregulators such as SIN3A and SIN3B, RNA helicase, chloride channel receptors and preferentially target cancer stem-cell like population. Importantly, the <i>in vitro</i> and <i>in vivo</i> antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies done in healthy and parasited patients. Thus, existing information on ivermectin could allow its rapid move into clinical trials for cancer patients.</p>
<p>&nbsp;</p>
<p>Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/</p>
<p><br>&nbsp;</p>
